Zevra Q2 2025 net revenue at $25.9mln, arimoclomol approval sought in EU

• Q2 2025 net revenue: $25.9 million • Product net revenue: $21.8 million • PRV sale: $150 million • Arimoclomol MAA submission to EMA • Balance sheet bolstered for commercial launches and dev. programs • Conference call TODAY at 4:30 p.m. ET

Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) has reported its financial results for the second quarter of 2025, highlighting significant growth and strategic advancements in its rare disease therapy portfolio. The company's net revenue for Q2 2025 reached $25.9 million, driven primarily by product net revenue of $21.8 million [1].

A key milestone in the quarter was the completion of the sale of Zevra's Pediatric Rare Disease Priority Review Voucher (PRV) for $150.0 million, which bolstered the company's balance sheet and provided non-dilutive capital for commercial launches and development programs [1]. This sale was a significant boost to the company's financial stability, positioning it to continue its growth trajectory.

Zevra also made progress in expanding its reach globally by submitting a Marketing Authorisation Application (MAA) to the European Medicines Agency (EMA) for the evaluation of arimoclomol for the treatment of Niemann-Pick Disease Type C (NPC). Arimoclomol, marketed as MIPLYFFA in the U.S., has shown promising clinical results in halting disease progression and reducing unesterified cholesterol in NPC patients [1].

The company's commercial efforts were further underscored by the enrollment of 7 patients in the Phase 3 DiSCOVER trial of celiprolol for the treatment of Vascular Ehlers-Danlos Syndrome during Q2 2025, bringing the total number of enrolled patients to 39 [1]. This trial is part of Zevra's pipeline of innovative therapies aimed at addressing unmet medical needs.

Zevra's financial performance was also notable for its robust cash position, with cash, cash equivalents, and securities totaling $217.7 million as of June 30, 2025. This financial flexibility allows the company to execute on its strategic priorities without relying on external capital markets [1].

To discuss these developments, Zevra will host a conference call and audio webcast today at 4:30 p.m. ET. Investors and interested participants can access the call via the company's website [1].

References:
[1] https://www.nasdaq.com/press-release/zevra-reports-second-quarter-2025-financial-results-and-corporate-update-2025-08-12